Navigation Links
FDA Grants Orphan Drug Designation to TREANDA, an Investigational Treatment for Chronic Lymphocytic Leukemia
Date:8/29/2007

FRAZER, Pa., Aug. 29 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) announced today that the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development granted orphan drug designation for the company's investigational therapy, TREANDA(R) (bendamustine HCl), for the treatment of chronic lymphocytic leukemia (CLL). According to the National Cancer Institute, CLL is a slowly progressing blood and bone marrow disease with an estimated 15,000 new cases diagnosed every year in the United States.

Orphan drug status is granted by the FDA to promote the development of products that demonstrate promise for the treatment of rare diseases affecting less than 200,000 Americans annually. The orphan drug designation would entitle Cephalon to a seven-year period of marketing exclusivity in the United States for TREANDA, if approved by FDA for the treatment of CLL.

In the third quarter of 2007, Cephalon plans to submit a new drug application to the FDA for TREANDA for the treatment of patients with CLL. The company also is studying TREANDA for the treatment of patients with indolent (or slowly-progressing) non-Hodgkin's lymphoma (iNHL), who are refractory to the monoclonal antibody rituximab.

Cephalon is committed to advancing medications for orphan diseases. The company's first product, PROVIGIL(R) (modafinil) Tablets [C-IV], was launched with an orphan drug designation for narcolepsy in 1999. Other Cephalon therapies with orphan drug designation include TRISENOX(R) (arsenic trioxide) injection and CEP-701 (lestaurtinib), which is in development.

About TREANDA

TREANDA is the first rationally designed purine analog / alkylator hybrid, combining the moieties of an antimetabolite and an alkylator. Preclinical data show that TREANDA induces rapid, sustained single- and double-strand DNA damage, which results in apoptosis, or programmed cell death in the tumor. TREANDA also induces mitotic checkpoint inhibition, which resu
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. State to offer $850K in high-tech training grants
2. Grants worth $800,000 help BellBrook Labs develop products
3. Venture-backed firms could become eligible for federal SBIR grants
4. Mithridion wins grants for Alzheimers research
5. NASDAQ grants Merge more time for compliance
6. Morgridge seed grants attract over 220 proposals
7. Medical College researchers win federal grants
8. NSF grants bolster integrative graduate study at UW-Madison
9. Three state businesses receive technology grants
10. SBC Foundation awards technology grants in Wisconsin
11. Visonex plans to expand with state grants, loan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/29/2015)... ... 2015 , ... The StampedeCon 2015 Big Data Conference will be ... a row, will bring top technology professionals to St. Louis. Top industry speakers will ... and technology. The event is proudly sponsored by DataStax, Cisco, World Wide Technology, Hortonworks, ...
(Date:6/29/2015)... Elsevier , a world-leading ... services, today announced the highlights of its journal Impact ... Citation Reports® (JCR) published by Thomson Reuters, Elsevier saw ... to 2014, ahead of the aggregate across other journals. ... 62 subject categories, up from 61 in 2013. ...
(Date:6/26/2015)... - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ICO) ... in the management information circular dated June 1, 2015 were ... of Shareholders, held earlier today, June 26 2015. ... nominees proposed by management were elected as Directors ... next Annual Meeting of Shareholders or until their ...
(Date:6/26/2015)... and MUMBAI, India , ... 532540, NSE: TCS) a leading global IT services, consulting ... designated as a Leader in Worldwide Life Sciences R&D ... the " IDC MarketScape: Worldwide Life Science R&D Risk-Based ... report. The report evaluated eight leading IT ...
Breaking Biology Technology:StampedeCon Announces 2015 Agenda 2StampedeCon Announces 2015 Agenda 3Elsevier Announces 2014 Citation Impact Highlights 2Elsevier Announces 2014 Citation Impact Highlights 3iCo Therapeutics Announces Voting & Election Results from Annual Meeting of Shareholders 2iCo Therapeutics Announces Voting & Election Results from Annual Meeting of Shareholders 3TCS Recognized as a Leader in Life Sciences R&D Risk-Based Monitoring by IDC MarketScape 2TCS Recognized as a Leader in Life Sciences R&D Risk-Based Monitoring by IDC MarketScape 3TCS Recognized as a Leader in Life Sciences R&D Risk-Based Monitoring by IDC MarketScape 4
... ,, HARBIN, China , ... One Medical,Inc. ("China Sky One Medical" or "the ... pharmaceutical company producing over-the-counter drugs in, the People,s ... its Tian Long,Pharmaceutical Company ("Tian Long") subsidiary successfully ...
... May 27 /PRNewswire-Asia-FirstCall/ -- Concord Medical Services,Holdings Limited ("Concord ... the largest network of radiotherapy and diagnostic imaging centers,in China ... March 31, 2010 (1). , , First ... in the first quarter of 2010 were RMB76.2 million, ...
... 27, 2010 , , , ... - New Trial Results on ExoSeal(TM) Vascular Closure Device Support its,Clinical Safety* and Efficacy ... Cordis Corporation, a worldwide ... Vascular Closure Device. ExoSeal(TM) incorporates a number of new,advances in technology and simplicity of ...
Cached Biology Technology:China Sky One Medical Receives GMP Re-Certification 2China Sky One Medical Receives GMP Re-Certification 3Concord Medical Announces First Quarter 2010 Financial Results 2Concord Medical Announces First Quarter 2010 Financial Results 3Concord Medical Announces First Quarter 2010 Financial Results 4Concord Medical Announces First Quarter 2010 Financial Results 5Concord Medical Announces First Quarter 2010 Financial Results 6Concord Medical Announces First Quarter 2010 Financial Results 7Concord Medical Announces First Quarter 2010 Financial Results 8Concord Medical Announces First Quarter 2010 Financial Results 9Concord Medical Announces First Quarter 2010 Financial Results 10Concord Medical Announces First Quarter 2010 Financial Results 11Concord Medical Announces First Quarter 2010 Financial Results 12Concord Medical Announces First Quarter 2010 Financial Results 13Concord Medical Announces First Quarter 2010 Financial Results 14Concord Medical Announces First Quarter 2010 Financial Results 15CORDIS Launches ExoSeal(TM) Vascular Closure Device 2CORDIS Launches ExoSeal(TM) Vascular Closure Device 3CORDIS Launches ExoSeal(TM) Vascular Closure Device 4
(Date:6/24/2015)... 2015 The biologics safety testing market is ... the market include growth of the pharmaceutical and biological ... Over the years, the number of drug approvals in ... the FDA approved 225 drug applications and Health Canada ... Europe accounted for 3,822 of the pharmaceutical ...
(Date:6/23/2015)... , June 23, 2015   MedNet Solutions ... supports the entire spectrum of clinical research, is ... ™ , the company,s intuitive, flexible and ... a Silver 2015 Stevie® Award by the ... & Services Website category.  The American Business Awards ...
(Date:6/18/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the ... commerce market announces that its Wocket® smart wallet will be ... Mark", scheduled to air on WABC Radio (am770) in ... The broadcast air- time for the extensive ... NXT-ID, Inc.,s CEO Gino Pereira will be discussing ...
Breaking Biology News(10 mins):Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 3Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 4MedNet Solutions' iMedNet eClinical Wins Silver Stevie Award 2NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 2NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 3
... cancer researchers Robert Weinberg, a Founding Member of Whitehead ... for Experimental Cancer Research (ISREC) have updated their seminal ... study of cancer and the development of therapeutics for ... their original work, which codified the traits that all ...
... North Grafton, Mass., March 16, 2011 The ... varies as widely as owner,s perceptions about them, according ... at the Cummings School of Veterinary Medicine at Tufts ... nutritional needsboth for humans and petschange with aging, the ...
... MaxID, a leading provider of mobile identity solutions and ... in India are pleased to announce that they have teamed ... and software driven by the efforts of the Unique Identification ... is extremely fortunate to be working with I.D. Solutions in ...
Cached Biology News:Whitehead scientist helps revisit 'Hallmarks of Cancer' 2Whitehead scientist helps revisit 'Hallmarks of Cancer' 3Wide variety in nutritional content found in 'senior' dog foods 2Wide variety in nutritional content found in 'senior' dog foods 3MaxID and I.D. Solutions Team Up to Address the Indian Identity Market 2MaxID and I.D. Solutions Team Up to Address the Indian Identity Market 3